Table 2. Factors associated with non-persistence (defined as a gap of 90 days) at 5 years of follow-up among women on hormonal therapy with or without metastases, in EGB database, according to multivariate Cox analysis.

	All cohort N=600		Subcohort of women without metastases N=564
	Adjusted hazard ratio (95% CI)	P-value	Adjusted hazard ratio (95% CI)	P-value
Age – years		0.436		0.255
(50–69) vs <50	0.84 (0.59–1.19)		0.75 (0.52–1.10)
⩾70 vs <50	0.99 (0.66–1.50)		0.92 (0.61–1.40)
Hormonal therapya		0.002		0.005
Tamoxifen vs AI	1.61 (1.20–2.17)		1.54 (1.14–2.11)
Number of switchesa
1 vs 0	3.10 (2.20–4.36)		3.49 (2.45–4.96)
⩾2 vs 0 or 1	2.48 (1.39–4.44)		2.65 (1.48–4.76)
In the 12-month period before inclusion
Affiliation to CMU-c		0.639		0.959
Yes vs No	1.18 (0.60–2.32)		1.02 (0.50–2.09)
Breast cancer ALD		<0.001		<0.001
Yes vs No	0.21 (0.13–0.32)		0.20 (0.12–0.31)
Breast cancer chemotherapy		0.007		<0.001
Yes vs No	0.65 (0.48–0.89)		0.56 (0.40–0.79)
Breast cancer metastases		<0.001	—	—
1 vs 0	3.07 (1.73–5.46)
⩾2 vs 0	4.25 (2.06–8.78)

Abbreviations: AI=aromatase inhibitors; ALD=registration with one of the 30 major long-standing diseases (Affection Longue Durée), CI=confidence interval; CMU-c=full healthcare coverage for patients with low income (Couverture Médicale Universelle); EGB=Echantillon Généraliste de Bénéficiaires.

^aTime-dependent variables.